Cargando…
ISCHEMIA Trial and the Significance of MI
During the past decade, the treatment of choice for chronic coronary syndromes (CCS) has been a contentious issue. Whether revascularisation, either percutaneous or surgical, or optimal medical therapy, offers better prognosis in terms of mortality, MI, and symptom relief, has yet to be confirmed. T...
Autores principales: | Arias, Eduardo A, Damas-de los Santos, Félix, Ontiveros-Mercado, Heriberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607381/ https://www.ncbi.nlm.nih.gov/pubmed/33163087 http://dx.doi.org/10.15420/icr.2020.15 |
Ejemplares similares
-
Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed
por: Giblett, Joel P, et al.
Publicado: (2020) -
A Review of the Impella Devices
por: Zein, Rami, et al.
Publicado: (2022) -
Use of Optical Coherence Tomography in MI with Non-obstructive Coronary Arteries
por: Karamasis, Grigoris, et al.
Publicado: (2022) -
Functionally Complete Coronary Revascularisation in Patients Presenting with ST-elevation MI and Multivessel Coronary Artery Disease
por: Di Serafino, Luigi, et al.
Publicado: (2021) -
Prognostic Value of Myocardial Blush Grade in ST-elevation MI: A Systematic Review and Meta-analysis
por: Vera Cruz, Patrick, et al.
Publicado: (2022)